

Anna LÃ³pez-Ferrer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9617557/publications.pdf>

Version: 2024-02-01

29
papers

559
citations

687220

13
h-index

642610

23
g-index

33
all docs

33
docs citations

33
times ranked

820
citing authors

#	ARTICLE	IF	CITATIONS
1	ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. Journal of the American Academy of Dermatology, 2016, 74, 1066-1072.	0.6	65
2	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. Journal of Dermatological Treatment, 2019, 30, 424-429.	1.1	57
3	Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 553-559.	1.3	51
4	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. British Journal of Dermatology, 2013, 169, 1141-1147.	1.4	46
5	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. Journal of Dermatological Treatment, 2018, 29, 334-346.	1.1	39
6	Biosimilars for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2019, 19, 993-1000.	1.4	30
7	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2821-2829.	1.3	24
8	The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opinion on Drug Safety, 2017, 16, 733-742.	1.0	23
9	Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1728-1736.	1.3	21
10	Secukinumab (AIN457) for the treatment of psoriasis. Expert Review of Clinical Immunology, 2015, 11, 1177-1188.	1.3	20
11	Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. British Journal of Dermatology, 2021, 185, 660-662.	1.4	17
12	Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy, 2022, 35, e15231.	0.8	17
13	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment, 2017, 28, 623-630.	1.1	16
14	Vismodegib: revisión. Actas Dermo-sifiligráficas, 2014, 105, 744-751.	0.2	13
15	Crusted (Norwegian) scabies: an under-recognized infestation characterized by an atypical presentation and delayed diagnosis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 483-485.	1.3	13
16	Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 422-430.	1.3	11
17	Artritis psoriásica. Medicina Clínica, 2022, 159, 40-46.	0.3	9
18	Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. Journal of Dermatological Treatment, 2020, 31, 222-226.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Anlisis de coste-eficacia incremental de los tratamientos biolgicos para la psoriasis en los momentos de valoracin significativos para la prctica clnica. Actas Dermo-sifiliogrficas, 2014, 105, 951-953.	0.2	7
20	Modelo de eficiencia de los frmacos biolgicos en el tratamiento de la psoriasis moderada-grave durante un ao en las condiciones de uso en Espaa. Actas Dermo-sifiliogrficas, 2016, 107, 34-43.	0.2	7
21	Artritis psoritica: lo que el dermatlogo debe saber (Parte 1). Actas Dermo-sifiliogrficas, 2010, 101, 578-584.	0.2	6
22	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy, 2022, 44, 725-730.	1.0	6
23	Etanercept en el tratamiento de la artritis psoritica. Actas Dermo-sifiliogrficas, 2015, 106, 252-259.	0.2	4
24	Adaptacin lingstica y cultural al espaol del cuestionario Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4). Actas Dermo-sifiliogrficas, 2020, 111, 655-664.	0.2	4
25	Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. Journal of Dermatological Treatment, 2022, 33, 2878-2880.	1.1	4
26	Triple paradoxical reaction due to adalimumab. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e71-e73.	1.3	3
27	Unidades psoriasis-artritis: 3 aos despus. Actas Dermo-sifiliogrficas, 2018, 109, 101-103.	0.2	1
28	Sesgo en el Cuestionario de productividad laboral y deterioro de las actividades: psoriasis (WPAI:PSO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	0
29	AB0770...DESCRIBING A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS ACCORDING TO THE BODY MASS INDEX: EXPERIENCE IN A JOINT RHEUMATOLOGY-DERMATOLOGY CLINIC. Annals of the Rheumatic Diseases, 2020, 79, 1683.1-1683.	0.5	0